Recent trends in prostate cancer in Spain

Cayuela, L.; Lendínez-Cano, G.; Chávez-Conde, M.; Rodríguez-Domínguez, Susana; Cayuela, Aurelio

doi:10.1016/j.acuroe.2020.05.010

Cited by 5 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main finding of this study is the change in the trend of incidence that occurred from 2003 onwards. From 1994 to 2003, it increased significantly, with an APC of 6%; the incidence rate then decreased to 2.7% from 2003 to 2018, similarly to the trend observed in other studies for the same period [ 22 , 23 ]. According to the data published by the Spanish Network of Cancer Registries (REDECAN), no decrease in incidence was observed in Spain prior to 2004 [ 24 ].…”

Section: Discussionsupporting

confidence: 86%

“…This observational study shows a slight and continuous decline in mortality rates during the period observed, without identifying any changing trends. In Spain, a declining trend in mortality rates was observed by Etxebarria et al [ 35 ] for the period 1995–2013, with a similar APC percentage, and by Cayuela et al [ 22 ], identifying two different periods: APC of -3.3% for 1992–2008; and APC of -2.4% for 2008–2018. In fact, this decline has been observed across the board in developed countries, and is attributable to continuing therapeutic improvements combined with early diagnosis, as well as an improvement in the certification of cancer deaths [ 33 , 36 ].…”

Section: Discussionsupporting

confidence: 55%

“…According to the clinical data available for Girona, there was a progressive decrease and then stabilization in PSA testing from 2010 onwards, a trend similar to other published data [ 33 ]. As noted above, the clinical use of PSA tests to diagnose PCa may have contributed to the increased incidence observed during the first period analyzed, leading to early diagnosis and probably overdiagnosis, and inflating the incidence data by increasing the number of latent cases diagnosed in asymptomatic men [ 22 ]. In this respect, the subsequent decrease in the number of PSA tests entails a loss of opportunity to detect cases in early stages [ 33 , 34 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Significantly reduced incidence and improved survival from prostate cancer over 25 years

Serdà-Ferrer,

Sanvisens,

Fuentes-Raspall

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

Background Prostate cancer (PCa) was the second most frequent cancer and the fifth leading cause of cancer death among men in 2020. The aim of this study was to analyze trends in the incidence, mortality and survival of PCa in Girona, Spain, over 25 years. Methods Population-based study of PCa collected in the Girona Cancer Registry, 1994–2018. Age-adjusted incidence and mortality rates were calculated per 100,000 men-year. Joinpoint regression models were used for trends, calculating the annual percentage changes (APC). Observed and net survival were analyzed using Kaplan–Meier and Pohar-Perme estimations, respectively. Results A total of 9,846 cases of PCa were registered between 1994–2018. The age-adjusted incidence and mortality rates were 154.7 (95%CI: 151.7 157.8) and 38.9 (95%CI: 37.3 –40.6), respectively. An increased incidence of 6.2% was observed from 1994 to 2003 (95%CI: 4.4 –8.1), and a decrease of -2.7% (95%CI: -3.5 –;-1.9) between 2003 and 2018. Mortality APC was -2.6% (95%CI: -3.3 –-2.0). Five-year observed and net survival were 72.8% (95%CI: 71.8 – 73.7) and 87.2% (95%CI: 85.9 – 88.4), respectively. Five-year net survival increased over time from 72.9% (1994–1998) to 91.3% (2014–2018). Conclusions The analyses show a clear reduction in PCa incidence rates from 2003 on, along with an increase in overall survival when comparing the earlier period with more recent years.

show abstract

Section: Discussionsupporting

confidence: 86%

Section: Discussionsupporting

confidence: 55%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Significantly reduced incidence and improved survival from prostate cancer over 25 years

Serdà-Ferrer,

Sanvisens,

Fuentes-Raspall

et al. 2023

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…Concurrently, the number of triadic combinations of chronic conditions that included prostate problems within the top 100 dropped from 30 to 21 during the same period. Possible reasons include both better treatment and fewer diagnoses of prostate disorders due to new recommendations in prostate cancer screening in older men [ 39 , 40 ]. Among multimorbid women, triadic combinations including osteoarthrosis, back pain and/or hypertension were most prevalent, with little change over time.…”

Section: Discussionmentioning

confidence: 99%

Shifts in Chronic Disease Patterns Among Spanish Older Adults With Multimorbidity Between 2006 and 2017

Spijker,

Rentería

2023

Int J Public Health

View full text Add to dashboard Cite

Objectives: To investigate changes in multimorbidity patterns among Spanish older adults.Methods: Data come from the Spanish National Health Survey (ENSE) for individuals aged 60–89 years (2006: n = 9,758; 2017: n = 8,535). Prevalence rates and relative risks of 20 chronic conditions are estimated for the multimorbidity (3+ chronic conditions) sample, along with observed-to-expected prevalence of three-way disease combinations. Principal component and cluster analyses identify multimorbidity patterns and track temporal changes.Results: Overall, multimorbidity remained stable [2006: 59.6% (95% CI: 58.7%–60.6%); 2017: 60.3% (CI: 59.3%–61.3%)], except at older ages. Women exhibited higher multimorbidity prevalence, but sex differences declined by five percentage points. Low-high education differences widened by three percentage points. In 2017 most individuals living with multimorbidity experienced hypertension (63.4%), osteoarthrosis (62.4%) and chronic back pain (55.9%). These chronic conditions also dominate the most common triadic combinations. Multimorbid men also saw increases in cholesterol and diabetes.Conclusion: Multimorbidity trends and the most common combination of diseases can help plan healthcare for an ageing population. Sex and socioeconomic differences pose additional public health challenges as women and deprived populations tend to have more health complexities.

show abstract

“…Among the most prevalent cancers, prostate cancer (PCa) is the second most common type with an estimated 1.4 million new cases and 375,000 deaths worldwide per year [ 7 , 8 , 9 ]. Previous studies have shown that advanced age is the primary risk factor, with more than 75% of all PCas being diagnosed in men over 65 years of age [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

Analysis of Frailty Syndrome in Men with Metastatic Prostate Cancer: A Scoping Review

Mafla-España

Torregrosa

Cauli

2023

JPM

View full text Add to dashboard Cite

Most patients with metastatic prostate cancer (mPCa) are older. In addition, current geriatric oncology guidelines suggest that all cancer patients aged over 70 years should undergo a comprehensive geriatric assessment (CGA), with the identification of frailty syndrome being crucial for clinical decisions. Frailty can be associated with lower quality of life (QoL) and interfere with the feasibility or side effects of oncology treatments. Methods: We performed a systematic literature search to evaluate frailty syndrome and associated alterations related to CGA impairment by searching in different academic databases (PubMed, Embase, and Scopus). The identified articles were reviewed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Results: Of the 165 articles consulted, 7 met our inclusion criteria. Analysis of data related to frailty syndrome in patients with mPCa showed a prevalence between 30–70% depending on the tool used. Additionally, frailty was associated with other CGA assessments and QoL evaluation outcomes. In general terms, CGA scores for patients with mPCa were lower than those for patients without metastasis. Furthermore, functional QoL appeared to be worse for patients with metastasis, and global QoL (burden) was more strongly associated with frailty. Conclusion: Frailty syndrome was related to a poorer QoL in patients with mPCa and its evaluation should be considered in clinical decision-making and when choosing the most appropriate active treatment, if any, to increase survival.

show abstract

Recent trends in prostate cancer in Spain

Cited by 5 publications

References 25 publications

Significantly reduced incidence and improved survival from prostate cancer over 25 years

Significantly reduced incidence and improved survival from prostate cancer over 25 years

Shifts in Chronic Disease Patterns Among Spanish Older Adults With Multimorbidity Between 2006 and 2017

Analysis of Frailty Syndrome in Men with Metastatic Prostate Cancer: A Scoping Review

Contact Info

Product

Resources

About